

Review

Neurosurg Rev. 2025 Aug 8;48(1):595. doi: 10.1007/s10143-025-03739-z.

# Bibliometric analysis of publication trends in meningioma research (1992 – 2023)

Xulei Huo<sup>1 2</sup>, LiWei Wang<sup>1 2</sup>, Junpeng Ma<sup>1 2</sup>, Zhen Wu<sup>1 2</sup>, Ke Wang<sup>3 4</sup>

Affiliations

PMID: 40779080 DOI: [10.1007/s10143-025-03739-z](https://doi.org/10.1007/s10143-025-03739-z)

## Abstract

The purpose of this study was providing an overview of meningioma research and its current situation. We conducted a bibliometric study of 14,027 articles and reviews on meningioma between January, 1992 to June, 2023 with the bibliometrix tool and VOSviewer. The distribution of authorship and collaboration patterns among countries, institutions, publications, and authors were analyzed. Core sources was analyzed with Bradford's law and author productivity was analyzed with Lotka's Law. The current situation and key areas were assessed through co-occurrence analysis. The number of publications has steadily increased over the years. The United States and University California San Francisco made the most contribution country and institution, respectively. Among the cited authors, Zhang J. emerged as the leading contributor while Perry A. was the most productive. Black P.M. had the highest h-index and Nassiri F. ranked first among the m-index. The most frequently cited study was Louis D.N. et al.'s 2016 publication in Acta Neuropathologica, titled "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary." The journals with the most published articles and most cited publications were World Neurosurgery and Journal of Neurosurgery, respectively. According to keyword analysis, treatment option, chemotherapy, NF2 gene and estrogen receptor, and progesterone receptor are becoming more popular. This study provided a comprehensive overview of meningioma research, as well as potential future research fields, such as the chemotherapy and NF2 gene.

**Keywords:** Bibliometric analysis; Future outlook; Meningioma; Publication trends.

© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

[PubMed Disclaimer](#)